Pricing Log in Create free account

INmune Bio, Inc. (INMB) vs Serina Therapeutics, Inc. (SER)

INmune Bio, Inc. and Serina Therapeutics, Inc. are both Biotechnology companies. INmune Bio, Inc. and Serina Therapeutics, Inc. are of similar size ($45.8M and $45.5M). INmune Bio, Inc. grew revenue faster over the last twelve months: −51.6% against −94.2%. Across the 14 metrics below, INmune Bio, Inc. leads on 8 and Serina Therapeutics, Inc. on 6.

Valuation

Metric INMB SER Biotechnology median
P/E n/m n/m 8.50
P/S 310.73 160.23 9.71
P/B 2.06 1.55 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 210.43 66.04 9.21
Earnings yield (42.68%) (106.78%) (33.15%)
Free cash flow yield (39.17%) (73.10%) (25.50%)

Profitability

Metric INMB SER Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (74.82%) (306.22%) (56.36%)
Return on assets (57.08%) (136.00%) (48.04%)
Return on invested capital (646.94%) 0.00% 0.00%

Growth

Metric INMB SER Biotechnology median
Revenue growth (TTM) (51.61%) (94.21%) 6.02%
EPS growth (last fiscal year) 11.85% (26.49%) 30.26%
Revenue growth, 5-year CAGR 35.37% (18.48%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INMB SER Biotechnology median
Debt to equity 0.00 0.16 0.00
Current ratio 4.04 6.65 4.72
Net debt to EBITDA 0.52 0.00 0.96

Dividend

Metric INMB SER Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric INMB SER Biotechnology median
Market cap 45.80m 45.46m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack